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Abstract: CLINICAL CHARACTERISTICS: FKBP14 kyphoscoliotic Ehlers-Danlos syndrome (FKBP14-
kEDS) is characterized by congenital muscle hypotonia and weakness (typically improving during child-
hood), progressive scoliosis, joint hypermobility, hyperelastic skin, gross motor developmental delay,
myopathy, and hearing impairment. Most affected children achieve independent walking between ages
two and four years. A decline of motor function in adulthood may be seen, but affected individuals are
likely to be able to participate in activities of daily living in adulthood and maintain independent walk-
ing. Occasional features underlying systemic connective tissue involvement include aortic rupture and
arterial dissection, subdural hygroma, insufficiency of cardiac valves, bluish sclerae, bladder diverticula,
inguinal or umbilical herniae, and premature rupture of membranes during pregnancy. Rarer findings
may include bifid uvula with submucous or frank cleft palate, speech/language delay without true cog-
nitive impairment, and rectal prolapse. DIAGNOSIS/TESTING: Clinical diagnostic criteria rely on the
finding of congenital muscular hypotonia AND congenital or early-onset kyphoscoliosis in addition to
generalized joint hypermobility or further gene-specific and/or supportive clinical features. The diagnosis
of FKBP14-kEDS is established in a proband by the identification of biallelic pathogenic variants in
FKBP14 by molecular genetic testing. MANAGEMENT: Treatment of manifestations: In those with
aortic dilation or vascular dissection, use of beta blockers may be considered; physical and occupational
therapy to address age-dependent decline in muscular strength; standard treatment for severe scoliosis,
clubbed foot, osteopenia/osteoporosis, refractive error, hearing impairment, and cleft palate. Surveil-
lance: Blood pressure measurement at each visit; neurodevelopmental assessment at each visit until
adolescence; evaluation by an orthopedic physician as clinically indicated but typically at least annually;
periodic ophthalmology and hearing evaluations (e.g., every 2-3 years); DEXA scan, echocardiogram with
consideration of cardiac MRI, and vascular ultrasonography every 2-5 years. Agents/circumstances to
avoid: Sports that place stress on the joints; contact sports in those with an aortic aneurysm; hyperten-
sion. Pregnancy management: An increased risk for miscarriage, premature rupture of membranes, and
rupture of arteries in affected pregnant women should be considered. Delivery in a medical center with
a high-risk perinatologist in attendance is recommended. GENETIC COUNSELING: FKBP14-kEDS is
inherited in an autosomal recessive manner. Each sib of an affected individual has a 25% chance of being
affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not
a carrier. Carrier testing for at-risk relatives and prenatal testing for a pregnancy at increased risk are
possible if both FKBP14 pathogenic variants have been identified in a family.
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Summary
Clinical characteristics
FKBP14 kyphoscoliotic Ehlers-Danlos syndrome (FKBP14-kEDS) is characterized by congenital muscle 
hypotonia and weakness (typically improving during childhood), progressive scoliosis, joint hypermobility, 
hyperelastic skin, gross motor developmental delay, myopathy, and hearing impairment. Most affected children 
achieve independent walking between ages two and four years. A decline of motor function in adulthood may be 
seen, but affected individuals are likely to be able to participate in activities of daily living in adulthood and 
maintain independent walking. Occasional features underlying systemic connective tissue involvement include 
aortic rupture and arterial dissection, subdural hygroma, insufficiency of cardiac valves, bluish sclerae, bladder 
diverticula, inguinal or umbilical herniae, and premature rupture of membranes during pregnancy. Rarer 
findings may include bifid uvula with submucous or frank cleft palate, speech/language delay without true 
cognitive impairment, and rectal prolapse.
Diagnosis/testing
Clinical diagnostic criteria rely on the finding of congenital muscular hypotonia AND congenital or early-onset 
kyphoscoliosis in addition to generalized joint hypermobility or further gene-specific and/or supportive clinical 
features. The diagnosis of FKBP14-kEDS is established in a proband by the identification of biallelic pathogenic 
variants in FKBP14 by molecular genetic testing.
Management
Treatment of manifestations: In those with aortic dilation or vascular dissection, use of beta blockers may be 
considered; physical and occupational therapy to address age-dependent decline in muscular strength; standard 
treatment for severe scoliosis, clubbed foot, osteopenia/osteoporosis, refractive error, hearing impairment, and 
cleft palate.
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Surveillance: Blood pressure measurement at each visit; neurodevelopmental assessment at each visit until 
adolescence; evaluation by an orthopedic physician as clinically indicated but typically at least annually; periodic 
ophthalmology and hearing evaluations (e.g., every 2-3 years); DEXA scan, echocardiogram with consideration 
of cardiac MRI, and vascular ultrasonography every 2-5 years.
Agents/circumstances to avoid: Sports that place stress on the joints; contact sports in those with an aortic 
aneurysm; hypertension.
Pregnancy management: An increased risk for miscarriage, premature rupture of membranes, and rupture of 
arteries in affected pregnant women should be considered. Delivery in a medical center with a high-risk 
perinatologist in attendance is recommended.
Genetic counseling
FKBP14-kEDS is inherited in an autosomal recessive manner. Each sib of an affected individual has a 25% 
chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected 
and not a carrier. Carrier testing for at-risk relatives and prenatal testing for a pregnancy at increased risk are 
possible if both FKBP14 pathogenic variants have been identified in a family.
Diagnosis
Formal clinical diagnostic criteria for FKBP14 Kyphoscoliotic Ehlers-Danlos syndrome (FKBP14-kEDS) were 
established in the 2017 revised Ehlers-Danlos syndrome (EDS) nosology [Malfait et al 2017]; see Establishing 
the Diagnosis.
Suggestive Findings
FKBP14 kyphoscoliotic Ehlers-Danlos syndrome (FKBP14-kEDS) should be suspected in individuals with 
kyphoscoliosis, severe congenital muscle hypotonia, and joint hypermobility
Major and minor clinical features of FKBP14 kyphoscoliotic EDS have been outlined as follows (adapted from 
Malfait et al [2017] and Giunta et al [2018b]).
Major clinical features
• Congenital muscular hypotonia
• Congenital or early onset kyphoscoliosis
• Generalized joint hypermobility
Gene-specific minor features
• Early onset sensorineural, conductive or mixed hearing impairment (see Clinical Description)
• Muscle atrophy
• Follicular hyperkeratosis
• Bladder diverticula
Other suggestive findings
• Marfanoid habitus
• Pectus deformity
• Talipes equinovarus
• Skin hyperextensibility
• Easily bruisable skin
• Hernia (umbilical or inguinal)
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• Rupture/aneurysm of a medium-sized artery
• Blue sclerae
• Refractive errors (myopia, hypermetropia)
• Osteopenia/osteoporosis
Supportive laboratory findings
• Normal or only slightly elevated serum creatine kinase (CK) level
• Histopathology of muscle biopsies showing nonspecific mild myopathic changes with increased variation 
in muscle fiber diameter to more pronounced changes with profound fiber atrophy and proliferation of 
fatty tissue
Note: At the moment, muscle biopsy is not required to make the diagnosis of FKBP14-kEDS.
Supportive imaging findings. MRI of the lower limbs that may demonstrate fatty degeneration of multiple 
muscle groups, including rectus femoris and soleus
Establishing the Diagnosis
Proposed minimal clinical diagnostic criteria for FKBP14-kEDS include the following [Malfait et al 2017]:
• Congenital muscular hypotonia AND congenital or early-onset kyphoscoliosis; PLUS
• Either or both of the following:
⚬ Generalized joint hypermobility
⚬ Three minor criteria (from either Gene-specific minor features or Other suggestive findings)
However, the diagnosis of FKBP14-kEDS is established in a proband by identification of biallelic pathogenic 
variants in FKBP14 by molecular genetic testing (see Table 1).
Gene-targeted testing requires that the clinician determine which gene(s) are likely involved, whereas genomic 
testing does not. Because the phenotype of FKBP14-kEDS is broad, individuals with the distinctive findings 
described in Suggestive Findings are likely to be diagnosed using gene-targeted testing (see Option 1), whereas 
those with a phenotype indistinguishable from many other inherited generalized connective tissue disorders are 
more likely to be diagnosed using genomic testing (see Option 2).
Option 1
When the phenotypic findings suggest the diagnosis of FKBP14-kEDS molecular genetic testing is indicated. 
Molecular genetic testing approaches can include single-gene testing or use of a multigene panel:
• Single-gene testing. Sequence analysis of FKBP14 detects small intragenic deletions/insertions and 
missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not 
detected.
Perform sequence analysis first. If only one or no pathogenic variant is found, perform gene-targeted 
deletion/duplication analysis to detect intragenic deletions or duplications.
Note: A common c.362dupC variant accounts for approximately 70% of disease alleles [Baumann et al 
2012, Giunta et al 2018b].
• A connective tissue disorder multigene panel that includes FKBP14 and other genes of interest (see 
Differential Diagnosis) is most likely to identify the genetic cause of the condition at the most reasonable 
cost while limiting identification of variants of uncertain significance and pathogenic variants in genes 
that do not explain the underlying phenotype. Note: (1) The genes included in the panel and the 
diagnostic sensitivity of the testing used for each gene vary by laboratory and are likely to change over 
FKBP14 Kyphoscoliotic Ehlers-Danlos Syndrome 3
time. (2) Some multigene panels may include genes not associated with the condition discussed in this 
GeneReview. (3) In some laboratories, panel options may include a custom laboratory-designed panel 
and/or custom phenotype-focused exome analysis that includes genes specified by the clinician. (4) 
Methods used in a panel may include sequence analysis, deletion/duplication analysis, and/or other non-
sequencing-based tests.
For an introduction to multigene panels click here. More detailed information for clinicians ordering genetic 
tests can be found here.
Option 2
When the phenotype is indistinguishable from many other inherited connective tissue disorders, comprehensive 
genomic testing (which does not require the clinician to determine which gene[s] are likely involved) is the best 
option. Exome sequencing is most commonly used; genome sequencing is also possible.
Exome array (when clinically available) may be considered if exome sequencing is non-diagnostic.
For an introduction to comprehensive genomic testing click here. More detailed information for clinicians 
ordering genomic testing can be found here.
Table 1. Molecular Genetic Testing Used in FKBP14 Kyphoscoliotic Ehlers-Danlos Syndrome
Gene 1 Method Proportion of Pathogenic Variants 
2 
Detectable by Method
FKBP14
Sequence analysis 3 24/24 4, 5
Gene-targeted deletion/duplication 
analysis 6 Unknown 
7
1. See Table A. Genes and Databases for chromosome locus and protein.
2. See Molecular Genetics for information on allelic variants detected in this gene.
3. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. 
Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon 
or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
4. Baumann et al [2012], Aldeeri et al [2014], Murray et al [2014], Dordoni et al [2016], Bursztejn et al [2017], Giunta et al [2018a], 
Castori et al [2019]. Note: The affected individual published by Bursztejn et al [2017] was initially published by Baumann et al [2012].
5. A common pathogenic variant (c.362dupC) has been reported; see Table 6.
6. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods used may include quantitative 
PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect 
single-exon deletions or duplications.
7. No data on detection rate of gene-targeted deletion/duplication analysis are available.
Clinical Characteristics
Clinical Description
FKBP14 kyphoscoliotic Ehlers-Danlos syndrome (FKBP14-kEDS) is characterized by congenital muscle 
hypotonia and weakness that typically improves during childhood, progressive scoliosis, joint hypermobility, 
hyperelastic skin, gross motor developmental delay, myopathy, and hearing impairment [Baumann et al 2012, 
Giunta et al 2018a]. Occasional features underlying systemic connective tissue involvement include aortic 
rupture and arterial dissection, subdural hygroma (potentially due to subdural bleeding or spontaneous 
intracranial hypotension), insufficiency of cardiac valves, bluish sclerae, bladder diverticula, inguinal or 
umbilical herniae, and premature rupture of membranes during pregnancy [Murray et al 2014, Dordoni et al 
2016, Giunta et al 2018a].
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A range of clinical severity is observed in individuals with FKBP14-kEDS for each of the systems discussed in 
this section [Baumann et al 2012, Brady et al 2017, Giunta et al 2018a].
Prenatal. Pregnancy involving an affected fetus is often characterized by reduced fetal movements and an 
increased risk of premature rupture of membranes.
Muscular features. Individuals with FKBP14-kEDS typically present at birth with congenital hypotonia and 
weakness. They often show feeding problems, and some will need airway management or respiratory support. 
Most affected infants have poor head control. With rare exceptions, motor developmental delay and reduced 
motor strength are common features in childhood, although muscle weakness typically improves during 
childhood [Giunta et al 2018a]. Most children achieve independent walking between ages two and four years. A 
decline of motor function in adulthood appears to represent an age-dependent feature in the natural course of 
this condition, but affected individuals are likely to be able to participate in activities of daily living in adulthood 
and maintain independent walking.
Wider phenotypic variability of the muscular features may exist, as suggested by the presence of early-onset 
muscle disease with severe involvement of the lower-limb muscles in one recently described affected individual 
[Castori et al 2019].
Skeletal/joint features
• Kyphoscoliosis is a hallmark of FKBP14-kEDS and is usually severe and progressive. Two thirds of affected 
individuals manifest kyphoscoliosis before age one year (range: birth–7 years in 15 affected individuals 
described by Giunta et al [2018a]). Progressive kyphoscoliosis may respond to bracing, but often surgery is 
needed. Severe kyphoscoliosis may lead to restrictive lung disease without need for assisted ventilation.
• Pronounced joint hypermobility (mean value of Beighton score 8/9) is seen in 23/23 affected individuals 
[Giunta et al 2018a] for the small joints and 21/23 for the large joints. Joint hypermobility usually 
decreases with age.
⚬ Hypermobility may result in recurrent joint dislocations/sprains or chronic pain (5/23 affected 
individuals reported).
⚬ Foot deformities that include congenital or postural talipes and pes planus / planovalgus have been 
found in 23/23 of affected individuals.
• Despite significant joint hypermobility, congenital contractures are present in up to one third of affected 
individuals and may impact the fingers, wrist, elbows, or knees (7/23). Congenital hip dislocation is 
present in 4/17 of affected individuals.
• Fractures probably due to osteopenia/osteoporosis from immobility occurred in 3/23.
• Atlantoaxial subluxation/instability has been reported in three individuals [Dordoni et al 2016, Giunta et 
al 2018a, Castori et al 2019].
Eyes. Refractive errors, myopia, and hypermetropia are moderately frequent, present in about two thirds of 
affected individuals. Blue sclerae are present in about one third of affected individuals.
Ears. Hearing impairment can manifest at birth, in early infancy, or even later in life [Giunta et al 2018a]. 
Sensorineural hearing impairment is the most frequent, present in about half of affected individuals; conductive 
hearing loss is present in up to one quarter. Hearing impairment (either conductive or sensorineural) may 
manifest later in life or remain subclinical, thus necessitating periodic investigations (see Management).
Cardiovascular. Vascular complications in adulthood and their possible occurrence in childhood suggests that 
cardiovascular investigations in the routine assessment and follow up of affected individuals is indicated (see 
Management). Cardiovascular complications can be congenital (septal defects in a minority) or acquired 
(usually mild mitral or pulmonary valve insufficiency or dilatation of the ascending aorta).
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Additionally, artery dissections occurred in two adult individuals (internal carotid artery and celiac artery) 
[Murray et al 2014, Giunta et al 2018a] and a pseudoaneurysm rupture occurred in one child (hypogastric 
artery) [Dordoni et al 2016].
Skin and integument. All individuals described to date have had a subjective finding of soft skin texture. 
Hyperextensibility was found in 17/23. Atrophic and hypertrophic scarring are seen in fewer than half of affected 
individuals, as is easy bruising. Additional findings may include follicular hyperkeratosis and crisscross palms/
soles.
Other findings
• Inguinal and/or umbilical hernia in about half of affected individuals (11/23), sometimes with redundant 
umbilical skin.
• Bifid uvula with submucous cleft palate or frank cleft palate (7/23)
• Speech or language delay (7/20); true intellectual disability is rare and may be unrelated in children of 
consanguineous relationships.
• Visceral complications, including large bladder diverticula (3/19) and (rarely) rectal prolapse.
Prognosis. It is unknown if life span in individuals with FKBP14-kEDS is reduced. One reported individual is 
alive at age 53 years [Giunta et al 2018a], demonstrating that survival into adulthood is possible. Since many 
adults with disabilities have not undergone advanced genetic testing, it is likely that adults with this condition 
are underrecognized and underreported.
Genotype-Phenotype Correlations
Genotype-phenotype correlations that predict risk for specific complications or clinical severity have not been 
reported to date.
Pathophysiology
The pathomechanism of FKBP14-kEDS is only partially understood [Baumann et al 2012]. Pathology findings 
include the following:
• Normal collagen biosynthesis and secretion of collagen types I, III, and V
• Disarray of the main components of the extracellular matrix (i.e., collagen type I, III, and VI; fibronectin; 
tenascins; thrombospondin) by indirect immunofluorescence on skin fibroblast from affected individuals
Type V collagen is organized in an extracellular network that is similar to control fibroblasts.
• Loss of the main receptors of collagens and fibronectin, α2β1 and α5β1 integrins.
• Marked enlargement of the ER cisterns with accumulation of flocculent material in skin cells of affected 
individuals by transmission electron microscopy
See also Molecular Pathogenesis.
Nomenclature
FKBP14-kEDS was initially referred to as a variant of Ehlers-Danlos syndrome with progressive kyphoscoliosis, 
myopathy, and hearing loss. Since the development of the 2017 EDS Nosology [Malfait et al 2017], it is known as 
kEDS-FKBP14, FKBP14-kEDS, and FKBP14-related kEDS.
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Prevalence
FKBP14-kEDS is rare; the exact prevalence is unknown. From its first description in 2012, 30 individuals are 
known to the Authors at the time of review (2019). A disease incidence of approximately 1:100,000 live births is 
a reasonable estimate. Prevalence does not vary by race or ethnicity.
Genetically Related (Allelic) Disorders
No phenotypes other than those discussed in this GeneReview are known to be associated with germline 
pathogenic variants in FKBP14.
Differential Diagnosis
Table 2. Disorders to Consider in the Differential Diagnosis of FKBP14 Kyphoscoliotic Ehlers-Danlos Syndrome
Differential Diagnosis 
Disorder Gene(s) MOI
Clinical Features of Differential Diagnosis Disorder
Overlapping w/FKBP14-kEDS Distinguishing from FKBP14-kEDS
PLOD1 kyphoscoliotic EDS PLOD1 AR
• Congenital muscular 
hypotonia
• Congenital/early onset 
kyphoscoliosis
• Generalized joint 
hypermobility
• Absence of hearing 
impairment
• ↑ ratio of urinary 
pyridinolines
Musculocontractural EDS
(OMIM 601776, 615539)
CHST14
DSE AR Joint hypermobility
• Characteristic 
craniofacial features
• Peculiar fingers (tapering, 
slender, cylindric)
Collagen type VI-related 
disorders
COL6A1
COL6A2
COL6A3
AD
AR
• Congenital muscular 
hypotonia
• Progressive 
kyphoscoliosis
• Joint hypermobility
• Follicular hyperkeratosis
• Myopathy on muscle 
biopsy 1
• Respiratory muscle 
failure
• Absence of skin 
hyperelasticity & easy 
bruising
• Absence of hearing 
impairment & 
cardiovascular problems
Spondylodysplastic EDS 
(spEDS)
(OMIM 130070, 612350, 
615349)
B4GALT7
B3GALT6
SLC39A13
AR
• Congenital muscular 
hypotonia
• Kyphoscoliosis 
(B3GALT6-spEDS)
• Joint hypermobility
• Pectus deformities
• Progressive short stature
• Primary skeletal 
involvement
• Dysplastic teeth
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Table 2. continued from previous page.
Differential Diagnosis 
Disorder Gene(s) MOI
Clinical Features of Differential Diagnosis Disorder
Overlapping w/FKBP14-kEDS Distinguishing from FKBP14-kEDS
Myopathic EDS
(OMIM 616471) COL12A1
AD
AR
• Congenital muscular 
hypotonia
• Motor developmental 
delay
• Soft, doughy skin
• Muscular atrophy
• Myopathy on muscle 
biopsy 1
• Severe progressive 
scoliosis
AD = autosomal dominant; AR = autosomal recessive; EDS = Ehlers-Danlos syndrome; MOI = mode of inheritance
1. In Bethlem myopathy, muscle biopsies reveal myopathic or dystrophic changes. Collagen VI immunolabeling is often normal or 
shows only subtle alterations. Conversely, in Ulrich congenital muscular dystrophy muscle biopsies more commonly show dystrophic 
features with degeneration and regeneration and replacement of muscle with fat and fibrous connective tissue. Collagen VI 
immunolabeling from the endomysium and basal lamina ranges from absent to moderately or markedly reduced, but may be normal 
around the capillaries (see Collagen Type VI-Related Disorders).
Management
Evaluations Following Initial Diagnosis
To establish the extent of disease and needs in an individual diagnosed with FKBP14 kyphoscoliotic Ehlers-
Danlos syndrome (FKBP14-kEDS), the evaluations summarized in Table 3 (if not performed as part of the 
evaluation that led to the diagnosis) are recommended.
Table 3. Recommended Evaluations Following Initial Diagnosis in Individuals with FKBP14-kEDS
System/Concern Evaluation Comment
Musculoskeletal
• Clinical & radiologic documentation of 
kyphoscoliosis & measurement of 
curvature
• Evaluation for joint contractures & other 
skeletal features 1
Referral to orthopedist
Physical therapy evaluation To develop a specific program to be followed by patient
Dual-energy X-ray absorptiometry (DEXA) In those w/frequent fractures or decreased ambulation
Eyes Ophthalmologic evaluation To evaluate for refractive errors
Ears Audiology evaluation A repeat hearing evaluation is recommended even if patient had normal newborn hearing screen.
Cardiovascular
Echocardiography
• To include measurement of aortic root size and 
assessment of heart valves
• Cardiac & abdominal ultrasound /MRI may also be 
considered to monitor for aortic dilatation.
Measurement of blood pressure Maintenance of blood pressure in normal range for age recommended to reduce risk of arterial rupture
Craniofacial Assessment of the palate for submucous or frank cleft Referral to craniofacial clinic if palatal anomalies are suspected
8 GeneReviews®
Table 3. continued from previous page.
System/Concern Evaluation Comment
Miscellaneous/
Other
Developmental assessment To include motor, speech/language evaluation, general cognitive, & vocational skills
Consultation w/clinical geneticist &/or genetic 
counselor
1. Care providers should be made aware of the possibility of atlantoaxial instability; however, proactive assessment for this finding is 
not typically done.
Treatment of Manifestations
Table 4. Treatment of Manifestations in Individuals with FKBP14-kEDS
Manifestation/
Concern Treatment Considerations/Other
Severe scoliosis Standard treatment, ideally in multidisciplinary setting
• Surgery may be indicated for severe scoliosis.
• At surgery caution should be taken due to risk for 
vascular complications, atlantoaxial instability, & primary 
muscle disease.
Clubbed foot/
Foot deformity
Standard treatment, ideally in 
multidisciplinary setting
Orthopedic shoe insoles may be beneficial for those w/foot 
deformity & joint instability
Osteopenia/
Osteoporosis Standard treatment
Age-dependent muscle 
decline Physiotherapy program
• Orthopedists, rehabilitation medicine, & physical & 
occupational therapists can assist in recommending 
appropriate devices to improve joint stability.
• Walker or wheelchair may be necessary for mobility.
Ocular refraction 
abnormality
Standard treatment(s) as 
recommended by ophthalmologist
Hearing impairment Standard treatment, which may include use of hearing aid See Hereditary Hearing Loss and Deafness Overview.
Aortic dilation/
Vascular dissection
Eventually, use of beta blockers in 
patients with aortic dilation to prevent 
further expansion
• Use of beta blockers (e.g., celiprolol) may be considered 
based on their efficiency in vascular EDS. 1
• Vascular surgery is extremely risky because of vascular 
fragility in EDS.
Cleft palate Standard treatment
1. Ong et al [2010]
Motor Dysfunction
Gross motor dysfunction
• Physical therapy is recommended to maximize mobility.
• Consider use of durable medical equipment as needed (e.g., wheelchairs, walkers, bath chairs, orthotics, 
adaptive strollers).
Fine motor dysfunction. Occupational therapy is recommended for difficulty with fine motor skills that affect 
adaptive function such as feeding, grooming, dressing, and writing.
Oral motor dysfunction. Assuming that the individual is safe to eat by mouth, feeding therapy (typically from 
an occupational or speech therapist) is recommended for individuals who have difficulty feeding due to poor 
oral motor control.
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Surveillance
Standardized medical surveillance guidelines for individuals with FKBP14-kEDS have not been published.
Table 5. Recommended Surveillance for Individuals with FKBP14-kEDS
System/Concern Evaluation Frequency
Musculoskeletal
Evaluations by orthopedic physician & specialist in 
rehabilitation medicine for managementof kyphoscoliosis, 
contractures, & foot deformities
As clinically indicated but at least annually
DEXA scan Every 2-5 yrs, or in those w/reduced ambulation
Eyes Routine ophthalmologic evaluation Every 2-3 years
Ears Formal hearing evaluation Every 2-3 years
Cardiovascular
Blood pressure measurement 1 At each visit
• Echocardiography w/consideration of cardiac MRI
• Vascular ultrasonography to evaluate abdominal 
&peripheral arteries & veins
Every 2-5 yrs starting in early childhood
Neurodevelopment Assessment of developmental progress At each visit until adolescence
1. Maintenance of blood pressure in the normal range for age is recommended to reduce the risk of arterial rupture.
Agents/Circumstances to Avoid
Avoid the following:
• For children with severe joint hypermobility, sports that place stress on the joints
• High blood pressure
• For individuals with aortic aneurysm, contact sports
Evaluation of Relatives at Risk
It is appropriate to clarify the genetic status of apparently asymptomatic older and younger at-risk relatives of an 
affected individual in order to identify as early as possible those who would benefit from prompt initiation of 
treatment and surveillance measures. Molecular genetic testing can be used if the pathogenic variants in the 
family are known.
See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.
Pregnancy Management
No pregnancies in women with FKBP14-kEDS have been reported to date. An increased risk for miscarriage, 
premature rupture of membranes, and rupture of arteries in affected pregnant women should be considered. 
Delivery in a medical center with a high-risk perinatologist in attendance is recommended.
Therapies Under Investigation
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on 
clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this 
disorder.
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Genetic Counseling
Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, 
and implications of genetic disorders to help them make informed medical and personal decisions. The following 
section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for 
family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may 
face or to substitute for consultation with a genetics professional. —ED.
Mode of Inheritance
FKBP14 kyphoscoliotic Ehlers-Danlos syndrome (FKBP14-kEDS) is inherited in an autosomal recessive manner.
Parents of a proband
• The parents of an affected child are obligate heterozygotes (i.e., carriers of one FKBP14 pathogenic 
variant).
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.
Sibs of a proband
• At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being 
an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
• Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.
Offspring of a proband. The offspring of an individual with FKBP14-kEDS are obligate heterozygotes (carriers) 
for a pathogenic variant in FKBP14.
Other family members. Each sib of the proband’s parents is at a 50% risk of being a carrier of a FKBP14 
pathogenic variant.
Carrier (Heterozygote) Detection
Carrier testing for at-risk relatives requires prior identification of the FKBP14 pathogenic variants in the family.
Related Genetic Counseling Issues
See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose 
of early diagnosis and treatment.
Family planning
• The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the 
availability of prenatal testing is before pregnancy.
• It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and 
reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.
DNA banking is the storage of DNA (typically extracted from white blood cells) for possible future use. Because 
it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in 
the future, consideration should be given to banking DNA of affected individuals.
Prenatal Testing and Preimplantation Genetic Diagnosis
Once the FKBP14 pathogenic variants have been identified in an affected family member, prenatal testing for a 
pregnancy at increased risk and preimplantation genetic diagnosis are possible.
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Differences in perspective may exist among medical professionals and within families regarding the use of 
prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather 
than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of 
the parents, discussion of these issues is appropriate.
Resources
GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries 
for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the 
information provided by other organizations. For information on selection criteria, click here.
• Association Francaise des Syndrome d'Ehlers Danlos (AFSED)
67, rue Jules Lecesne
Le Havre 76600
France
Phone: 0820 20 37 33
Email: contact@afsed.com
www.afsed.fr
• Ehlers-Danlos Society - Europe
35-37 Ludgate Hill
Office 7
London EC4M 7JN
United Kingdom
Phone: +44 203 887 6132
• Ehlers-Danlos Society Headquarters
P.O. Box 87463
Montgomery Village MD 20886
Phone: 410-670-7577
Email: info@ehlers-danlos.com
www.ehlers-danlos.com
• Ehlers-Danlos Support Group
PO Box 337
Aldershot Surrey GU12 6WZ
United Kingdom
Phone: 01252 690940
Email: director@ehlers-danlos.org
www.ehlers-danlos.org
• Ehlers-Danlos Support UK
PO Box 748
Borehamwood WD6 9HU
United Kingdom
Phone: 0208 736 5604; 0800 9078518
www.ehlers-danlos.org
• Medline Plus
Ehlers-Danlos Syndrome
• National Library of Medicine Genetics Home Reference
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• Ehlers-Danlos Society EDS & Related Disorders Global Registry
www.ehlers-danlos.com/eds-global-registry
Molecular Genetics
Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables 
may contain more recent information. —ED.
Table A. FKBP14 Kyphoscoliotic Ehlers-Danlos Syndrome: Genes and Databases
Gene Chromosome Locus Protein Locus-Specific 
Databases
HGMD ClinVar
FKBP14 7p14.3 Peptidyl-prolyl cis-
trans isomerase 
FKBP14
FKBP14 homepage - 
FKBP14 @ LOVD
FKBP14 FKBP14
Data are compiled from the following standard references: gene from HGNC; chromosome locus from OMIM; protein from UniProt. 
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click here.
Table B. OMIM Entries for FKBP14 Kyphoscoliotic Ehlers-Danlos Syndrome (View All in OMIM)
614505 FK506-BINDING PROTEIN 14; FKBP14
614557 EHLERS-DANLOS SYNDROME, KYPHOSCOLIOTIC TYPE, 2; EDSKSCL2
Molecular Pathogenesis
FKBP14 (transcript variant 1) encodes a 211-amino acid FKBP22 (alias FKBP14) protein, which contains a 
signal peptide of 18 residues and forms a dimer of identical subunits [Boudko et al 2014]. The protein consists of 
three domains:
• The PPIase catalytic domain (aa 45-135)
• The first EF-hand1 domain (aa 135-170)
• The second EF-hand2 domain (aa 179-211)
FKBP22 is an ER resident protein that belongs to the FK506-binding protein (FKBP) class of immunophilins, 
which have been implicated in catalyzing cis-trans-isomerization of peptidyl-prolyl peptide bonds and are 
supposed to accelerate protein folding. FKBP22 catalyzes the folding of type III collagen and interacts with type 
III collagen, type VI collagen, and type X collagen, but not with type I collagen, type II collagen, or type V 
collagen [Ishikawa & Bächinger 2014]. Remarkably, pathogenic variants in type III and type VI collagens cause 
the vascular type of EDS (vEDS) and COL6-related muscular dystrophies, respectively. Therefore, the clinical 
features of vascular abnormalities and myopathy documented in the affected individuals clearly correlates with 
the interaction of FKBP14 with type III and VI collagens [Giunta et al 2018a] (see also Pathophysiology).
Mechanism of disease causation. The majority of FKBP14 pathogenic variants are loss-of-function variants 
[Baumann et al 2012, Giunta et al 2018a]. The common c.362dupC frameshift, which is found with a frequency 
of approximately 70%, is the most common pathogenic variant [Baumann et al 2012, Giunta et al 2018a] and has 
been linked to the same haplotype in all individuals tested [Murray et al 2014].
A missense variant, p.Met48Lys [Giunta et al 2018a], and an in-frame deletion, p.Glu191del [Dordoni et al 
2016], have also been reported. Mapping of the missense variant p.Met48Lys onto the protein crystal structure 
near the potential PPIase active site of FKBP22 supports complete or partial loss of function of FKBP14 as a 
further disease mechanism in addition to loss of protein [Giunta et al 2018a].
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Western blot analysis using a FKBP14 mouse polyclonal antibody showed deficiency of FKBP14 in two 
individuals with FKBP14-kEDS [Baumann et al 2012].
FKBP14-specific laboratory technical considerations. FKBP14 consists of three small exons, a rather large 
fourth exon, which includes the 3' UTR, and three rather large introns. Transcript variants 2 and 3 are 
noncoding.
Table 6. Notable FKBP14 Pathogenic Variants
Reference Sequences DNA Nucleotide Change Predicted Protein Change Comment [Reference]
NM_017946.3
NP_060416.1
c.573_575del p.Glu191del Only in-frame variant reported [Dordoni et al 2016]
c.362dupC p.Glu122ArgfsTer7 Common pathogenic variant [Baumann et al 2012, Dordoni et al 2016, Giunta et al 2018a, Castori et al 2019]
c.143T>A p.Met48Lys Missense change reported near PPIase active site [Giunta et al 2018a]
Variants listed in the table have been provided by the authors. GeneReviews staff have not independently verified the classification of 
variants.
GeneReviews follows the standard naming conventions of the Human Genome Variation Society (varnomen.hgvs.org). See Quick 
Reference for an explanation of nomenclature.
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